Table 1. Demographic and Clinical Characteristics of the Patient Population.
| Characteristic | Patients, No. (%) | |||||
|---|---|---|---|---|---|---|
| Nirmatrelvir | Molnupiravir | Deaths (n = 645) | Hospitalization (n = 5368) | |||
| Treated (n = 22 594) | Untreated (n = 39 730)a | Treated (n = 5311) | Untreated (n = 39 351)a | |||
| Age, mean (SD), y | 61.8 (15.3) | 54.0 (19.8) | 65.8 (14.6) | 55.8 (19.1) | 76.8 (13.7) | 62.0 (18.3) |
| Age group, y | ||||||
| 12-49 | 4716 (21) | 16 483 (42) | 757 (14) | 14 957 (38) | 25 (4) | 1302 (24) |
| 50-64 | 6575 (29) | 9313 (23) | 1328 (25) | 9537 (24) | 84 (13) | 1280 (24) |
| 65-74 | 6781 (30) | 7209 (18) | 1704 (32) | 7547 (19) | 141 (22) | 1323 (25) |
| ≥75 | 4522 (20) | 6725 (17) | 1522 (29) | 7310 (19) | 395 (61) | 1463 (27) |
| Sex | ||||||
| Female | 13 581 (60) | 25 107 (63) | 2799 (53) | 24 457 (62) | 290 (45) | 3360 (63) |
| Male | 9013 (40) | 14 623 (37) | 2512 (47) | 14 894 (38) | 355 (55) | 2008 (37) |
| Race and ethnicity | ||||||
| Hispanic | 967 (4) | 2623 (7) | 178 (3) | 2512 (6) | 16 (3) | 212 (4) |
| Non-Hispanic Black | 1556 (7) | 6292 (16) | 320 (6) | 6357 (16) | 90 (14) | 739 (14) |
| Non-Hispanic White | 18 571 (82) | 27 542 (69) | 4499 (85) | 27 379 (70) | 493 (76) | 4094 (76) |
| Other or unknownb | 1500 (7) | 3273 (8) | 314 (6) | 3103 (8) | 46 (7) | 323 (6) |
| Ohio residency | 19 609 (87) | 34 325 (86) | 4637 (87) | 33 789 (86) | 566 (88) | 4931 (92) |
| SARS-CoV-2 immunity status | ||||||
| Vaccine boosters | 16 966 (75) | 19 795 (50) | 4162 (78) | 20 012 (51) | 326 (51) | 3168 (59) |
| Previously infected | 1816 (8) | 5131 (13) | 444 (8) | 5023 (13) | 52 (8) | 628 (12) |
| Coexisting conditions | ||||||
| Respiratory | 3994 (18) | 7629 (19) | 1242 (23) | 7696 (20) | 208 (32) | 1693 (32) |
| Immunocompromised | 1339 (6) | 2288 (6) | 960 (18) | 2889 (7) | 282 (44) | 1038 (19) |
| Cardiovascular system | 9472 (42) | 14 715 (37) | 3045 (57) | 15 663 (40) | 528 (82) | 3441 (64) |
| Diabetes | 3263 (14) | 5316 (13) | 1215 (23) | 5865 (15) | 235 (36) | 1362 (25) |
| Obesity | 3255 (14) | 5656 (14) | 901 (17) | 5721 (15) | 131 (20) | 1360 (25) |
| Other nonrespiratory | 10 200 (45) | 18 040 (45) | 3143 (59) | 18 570 (47) | 563 (87) | 4073 (76) |
| Socioeconomic index score, mean (SD) | 0.30 (0.09) | 0.33 (0.11) | 0.30 (0.09) | 0.33 (0.11) | 0.33 (0.11) | 0.31 (0.10) |
| Date of COVID-19 diagnosis | ||||||
| April 1 to June 21, 2022 | 3762 (17) | 9587 (24) | 649 (12) | 9374 (24) | 143 (22) | 951 (18) |
| June 22 to November 30, 2022 | 13 190 (58) | 22 041 (56) | 2778 (52) | 21 825 (56) | 372 (58) | 3033 (57) |
| December 1 to February 20, 2023 | 5642 (25) | 8102 (20) | 1884 (36) | 8152 (21) | 130 (20) | 1384 (26) |
a
Untreated denotes the patients who were eligible for the treatment but did not receive any COVID-19 treatments.
b
Other includes American Indian, Alaska Native, Asian, Native Hawaiian, Pacific Islander, and multiracial.